Harvard Bioscience, Inc.
HBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $19,662 | $24,958 | $91,865 |
| - Cash | $6,817 | $7,442 | $5,546 | $4,108 |
| + Debt | $7,332 | $43,314 | $44,607 | $44,495 |
| Enterprise Value | – | $55,534 | $64,019 | $132,252 |
| Revenue | $20,591 | $20,450 | $21,774 | $24,556 |
| % Growth | 0.7% | -6.1% | -11.3% | – |
| Gross Profit | $12,021 | $10,371 | $12,184 | $14,011 |
| % Margin | 58.4% | 50.7% | 56% | 57.1% |
| EBITDA | $1,156 | $155 | -$48,337 | $3,203 |
| % Margin | 5.6% | 0.8% | -222% | 13% |
| Net Income | -$1,231 | -$2,282 | -$50,340 | $18 |
| % Margin | -6% | -11.2% | -231.2% | 0.1% |
| EPS Diluted | -0.03 | -0.052 | -1.14 | 0 |
| % Growth | 41.7% | 95.5% | -285,100% | – |
| Operating Cash Flow | $830 | $2,755 | $2,986 | $1,725 |
| Capital Expenditures | -$207 | -$233 | -$513 | -$466 |
| Free Cash Flow | $623 | $2,522 | $2,473 | $1,259 |